171 patents
Page 3 of 9
Utility
SUMO inhibitor compounds and uses thereof
14 Feb 23
There are disclosed, inter alia, methods of inhibiting an E1 enzyme, and compounds useful for inhibiting an E1 enzyme.
Yuan Chen, Xiaohu Ouyang, Sung Wook Yi, Ted Charles Judd
Filed: 31 Jul 19
Utility
Stable dithizone solutions and formulations and methods for their use
14 Feb 23
An optimized Dipheylthiocarbazone or Dithizone (DTZ) solution was developed with preferred physical and chemical properties to characterize human islets and insulin producing cells differentiated from embryonic stem cells.
Ismail H. Al-Abdullah, Meirigeng Qi, Bashar Khiatah, Luis Valiente
Filed: 11 Mar 20
Utility
Compositions and methods of modulating macrophage activity
17 Jan 23
Disclosed herein, inter alia, are compositions and methods of modulating macrophage activity.
Jacob Berlin, Tom Haber, Yvonne Cornejo
Filed: 29 Jun 18
Utility
Nucleic acid-functionalized nanoparticles
10 Jan 23
Provided herein are functionalized nanoparticle compositions and methods of using the same.
Jacob Berlin, Pamela Tiet
Filed: 12 Feb 20
Utility
Methods of treating advanced prostate cancer
3 Jan 23
Provided herein are methods for treating metastatic prostate cancer using anti-androgen compounds and radionuclide-labeled androgens.
Zijie Sun, David Horne, Junfeng Li, John E. Shively, Jun Xie
Filed: 11 Feb 20
Utility
Genetically stable recombinant modified vaccinia Ankara (rMVA) vaccines and methods of preparation thereof
3 Jan 23
A vaccine comprising an immunologically effective amount of recombinant modified vaccinia Ankara (rMVA) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified H5 (mH5) promoter operably linked to a DNA sequence encoding a heterologous foreign protein antigen, wherein the expression of said DNA sequence is under the control of the mH5 promoter; b) generating rMVA virus by transfecting one or more plasmid vectors obtained from step a) into wild type MVA virus; c) identifying rMVA virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rMVA virus strain identified by step d); and f) purifying the rMVA viruses from step e) to form the vaccine.
Don Diamond, Zhongde Wang
Filed: 30 Mar 20
Utility
Phosphorothioate-conjugated peptides and methods of using the same
3 Jan 23
Provided herein are, inter alia, nucleic acid-peptide conjugates including a non-cell penetrating protein attached at its C-terminus to a phosphorothioate nucleic acid.
Andreas Herrmann, Hua Yu, Toshikage Nagao
Filed: 13 Jul 18
Utility
Multivalent oligonucleotide assemblies
27 Dec 22
Provided herein, inter alia, are double stranded oligonucleotide molecules and methods of making the molecules.
Piotr Swiderski
Filed: 3 Dec 19
Utility
Indirubin derivatives, and uses thereof
13 Dec 22
Indirubin is the major active anti-tumor component of a traditional Chinese herbal medicine used for treatment of chronic myelogenous leukemia (CML).
Sangkil Nam, Richard Jove, Leandros Skaltsounis
Filed: 7 Oct 19
Utility
HDAC8 inhibitors for treating cancer
22 Nov 22
Provided herein, inter alia, are compound and methods of treating cancer by inhibiting HDAC8.
Ya-Huei Kuo, Wei-Jan Huang, Chung-I Chang
Filed: 7 May 19
Utility
Methods, treatment, and compositions for characterizing thyroid nodule
22 Nov 22
The current disclosure provides, inter alia, method of determining benign nodules from thyroid cancer in a subject that is found to have a thyroid nodule, method of treating thyroid cancer in a subject detected to have thyroid cancer by the method of the current disclosure, compositions for determining benign nodules from thyroid cancer in a subject, and kits including reagents and composition for determining benign nodules from thyroid cancer in a subject.
Maria A. Hahn, John H. Yim, Yuman Fong, Arthur X. Li, Xiwei Wu
Filed: 22 Jul 16
Utility
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
11 Oct 22
The present disclosure relates to an isolated compound including a phosphorothioated oligodeoxynucleotide (ODN) sequence conjugated to a short-activating RNA (saRNA) or an antisense oligonucleotide sequence (ASO), compositions of such a compound, and method of treatment of cancer and autoimmune diseases (with or without stimulating immune response), method of immune stimulation, method of activating CEBPA, and method of reducing activity of STAT transcription factor, by one of the disclosed compounds or compositions.
Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Dayson Friaca Moreira
Filed: 24 Jul 20
Utility
Chimeric antigen receptors targeted to PSCA
11 Oct 22
Chimeric transmembrane immunoreceptors (CAR) targeted to PSCA are described.
Saul J. Priceman, Christine E. Brown, Stephen J. Forman
Filed: 6 Oct 16
Utility
Margin extension device and method
6 Sep 22
A margin extension device and method are disclosed herein.
Gagandeep Singh, Jonathan Kessler
Filed: 5 Aug 19
Utility
Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
6 Sep 22
Adeno-associated virus (AAV) Clade F vectors or AAV vector variants (relative to AAV9) for precise editing of the genome of a cell and methods and kits thereof are provided.
Saswati Chatterjee, Laura Jane Smith, Kamehameha Wong
Filed: 24 Apr 20
Utility
Coexpression of CAS9 and TREX2 for targeted mutagenesis
30 Aug 22
A composition used in targeted mutagenesis is provided, which includes a first expression cassette comprising a nucleotide sequence which encodes a CAS9 endonuclease; a second expression cassette comprising a nucleotide sequence which encodes a guide RNA sequence, wherein the guide RNA sequence is complementary to a target genome nucleotide sequence in a cell; and a third expression cassette comprising a nucleotide sequence which encodes a Trex2 exonuclease (Trex2) gene.
Jeremy M. Stark, Diana Yanez
Filed: 5 Dec 18
Utility
RNA aptamers against transferrin receptor (TfR)
30 Aug 22
A ribonucleic acid compound is disclosed, the ribonucleic acid compound comprising, or consisting of, an RNA sequence having at least 90% sequence identity to SEQ ID NO: 1, wherein said RNA sequence has a length of 29 nucleotides or fewer, and wherein the RNA sequence is capable of binding to a transferrin receptor (TfR).
John J. Rossi, Sorah Yoon, Nagy Habib
Filed: 10 Aug 18
Utility
Producing astrocytes using small molecules
16 Aug 22
Disclosed herein are methods of reprograming autologous tissues or cells into astrocytes or astroglial progenitor cells using one or more small molecule compounds only without any transgenes.
Yanhong Shi, E. Tian
Filed: 21 Jun 17
Utility
Neural stem cell-mediated cancer treatment
16 Aug 22
Provided are methods and compositions for treating cancer with a combination of neural stem cells (NSCs) and an oncolytic virus or a combination of oncolytic virotherapy and immune modulation.
Alexandra Jaqueline Annala, Karen Aboody, Jennifer Covello, Rachael Mooney
Filed: 29 Apr 19
Utility
Substrates for high-density cell growth and metabolite exchange
16 Aug 22
A polymer or other substrate optimized for growing cells is described, which takes the form of a micro-thin bag with gas permeable sides.
Yu-Chong Tai, Yang Liu, Colin A. Cook, Yuman Fong, Nanhai G. Chen
Filed: 10 Aug 18